[ad_1]
Donald Trump is sick with covid-19 and has been admitted to the Walter Reed Military Hospital in Washington DC
At the same time, he has already received a dose of a drug that has not yet been approved: the cocktail of polyclonal antibodies from the pharmaceutical company Regeneron.
– The president is exhausted, but in a good mood. His condition is being evaluated by a team of experts and together we will advise the president and Melania on future measures, the doctor said in a statement.
Within phase 3 studies
The drug the president has received is currently in phase 3 studies, the last phase before a drug is approved. This means that studies are conducted in large groups of patients to confirm the effect and safety of a treatment. On Tuesday, Regeneron released the first results of its studies, in which the company claimed the drug appears to reduce levels of the virus and relieve symptoms in patients who have not been hospitalized. The results should also have pointed to a reduction in the need for doctor visits.
Carrying out a small feasibility study.
The results only affected 275 out of 1,000 patients and the small feasibility study has yet to be reviewed, but so far it appears to be “very promising,” Dr. Jeanne Marrazzo tells CNN.
However, there are several questions surrounding the first results. The company has not said which people participated in the study, how representative they are. Nor have they presented how many patients needed hospital care despite treatment.
